Mr. Anton Bittner is Program Director at Kenai Therapeutics. He has extensive experience as a program manager, leading development teams to three Investigational New Drug applications and two drug approvals in both the United States and European Union. Mr. Bittner has over 20 years of experience as a drug discovery scientist, leading the functional genomics team at Janssen R&D in La Jolla, California, supporting the development of genomic tools to provide orthogonal measures of ADME, PK, and toxicology, and has 25 peer-reviewed publications. Over the past eight years, he has worked on drugs for four different orphan indications, including the CMC process development stage of Rylaze, now approved for the treatment of pediatric acute lymphoblastic leukemia. He has also led biosimilar product development, enabling treatment for patients that would otherwise not have access to disease altering therapy. Through this work, a biosimilar teriparatide was approved in both the United States and European Union, as well as in additional countries around the world. As a scientist, he managed translational biomarker work for several approved drugs including Remicade, Stelara, Infliximab and Spravato.

Mr. Bittner holds a Bachelor of Science in physiology and neuroscience from the University of California San Diego.